Skip to main content
. 2023 Sep 13;23:660. doi: 10.1186/s12884-023-05970-2

Table 5.

Effects of Allylestrenol versus Dydrogesterone on Endometrial Receptivity after PSM

Variables Dydrogesterone (N = 989) Allylestrenol (N = 989) P-value
Endometrial morphology (%) < 0.001*
 Type A 216 (29.7) 371 (37.9)
 Type B 509 (69.9) 608 (62.1)
 Type C 3 (0.4) 0 (0.0)
Endometrial perfusion (%) 0.588
 I 80 (11.0) 122 (12.6)
 II 644 (88.8) 846 (87.2)
 III 1 (0.1) 2 (0.2)
Endometrial thickness (cm) 0.97 (0.21) 1.00 (0.21) 0.031*
Uterine blood flow (artery)
 RI (left) 0.80 (0.07) 0.83 (0.34) 0.031*
 RI (right) 0.80 (0.10) 0.81 (0.06) < 0.001*
 PI (left) 2.02 (0.57) 2.20 (1.39) 0.001*
 PI (right) 1.96 (0.49) 2.10 (0.43) < 0.001*
 S/D (left) 5.43 (1.56) 6.03 (1.94) < 0.001*
 S/D (right) 5.32 (2.55) 5.82 (1.71) < 0.001*
Endometrial blood flow
 RI 0.52 (0.11) 0.51 (0.10) 0.042*
 PI 0.86 (2.02) 0.75 (0.22) 0.096
 S/D 2.13 (0.56) 2.08 (0.46) 0.087

PSM propensity score matching, RI resistance index, PI pulsatility index; S/D: peak systolic to diastolic velocity ratio

*P < 0.05

HHS Vulnerability Disclosure